Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...

Q4 2024 Earnings Call Transcript February 27, 2025 Altimmune, Inc. beats earnings expectations. Reported EPS is $-0.33, ...

Good day, ladies and gentlemen, and welcome to Altimmune fourth quarter and full year 2024 financial results conference call. As a reminder, this call is being recorded. (Operator Instructions) I ...

Earnings per share (EPS) was mostly in line with analyst estimates. Looking ahead, revenue is forecast to grow 66% p.a. on average during the next 3 years, compared to a 20% growth forecast for the ...

Altimmune Inc (ALT) reports a strong cash position and promising trial developments, despite increased expenses and ...

Shares of Altimmune Inc. (ALT) soared over 8% on Thursday, marking their best session in nearly three months, and extended ...

Piper Sandler analyst Yasmeen Rahimi initiated coverage on Avalo Therapeutics, Inc. AVTX with an Overweight rating and ...